Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Consensus Price Target from Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.00.

COYA has been the subject of a number of research analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. BTIG Research boosted their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, January 8th. Finally, Lake Street Capital restated a “buy” rating and set a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $4.84 on Monday. Coya Therapeutics has a 52-week low of $3.94 and a 52-week high of $8.29. The firm has a market capitalization of $101.25 million, a PE ratio of -4.36 and a beta of 0.27. The stock has a fifty day simple moving average of $5.25 and a two-hundred day simple moving average of $5.85.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $3.70 million. On average, sell-side analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Large investors have recently added to or reduced their stakes in the company. CM Management LLC raised its holdings in shares of Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after acquiring an additional 50,000 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth approximately $81,000. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. Lantern Wealth Advisors LLC bought a new stake in Coya Therapeutics during the 3rd quarter valued at about $66,000. Finally, Prosperity Wealth Management Inc. raised its stake in shares of Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after acquiring an additional 3,350 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.